证券代码：002737 证券简称：葵花药业 公告编号：2025-074 葵花药业集团股份有限公司 | 序 | | | | 金额 | | | 预期年化收 | 资金 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 签约机构 | 产品名称 | 产品类型 | | 起息日 | 到期日 | | | | 号 | | | | （万元） | | | 益率 | 来源 | | | 招商银行 | 招商银行聚益生金系 | 固定收益类 | | | | | 闲置 | | 1 | 哈尔滨平 | 列公司（35 天）B 款 | 非保本浮动 | 20,000.00 | 2025.11.14 | 2025.12.19 | | 2.1% 自有 | | | 房支行 | 理财计划 | 收益型 | | | | | 资金 | | | | 合计 | | 20,000.00 | | | | | 注：公司与上述签约机构不存在关联关系。 二、投资风险及风险控制措施 1 关于使用闲置自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性 ...

Group 1: Company Announcements - 合富中国's stock price increased by 256.29% over 14 trading days, significantly outperforming the industry and Shanghai Composite Index, leading to a suspension for verification starting November 17 [1] - 工业富联's GB300 achieved mass production in Q3, with improved yield and testing efficiency, positively impacting Q4 gross margin [2] - 天孚通信's controlling shareholder plans to transfer 8.5 million shares, representing 1.09% of total equity, due to personal funding needs [4] - 璞泰来 plans to invest 7.6 billion yuan in a new integrated film coating project, aiming to meet growing demand in the battery and energy storage sectors [5] - 电投能源 intends to acquire 100% of Baiyin Hua Coal Power for 11.149 billion yuan, financing through share issuance and cash [6] - 中微公司 reported that a shareholder completed a reduction of 12.52 million shares, totaling 3.351 billion yuan [7] - 瑞德智能 plans to invest 10 million yuan in a leading company in the power plant robotics sector [8] - 盘古智能 aims to acquire control of a petrochemical company by purchasing 11.97% of its shares for 24.64 million yuan [9] - 泰达股份 signed a memorandum for a waste-to-energy project in Egypt [10] - 杭氧股份 is set to establish a venture capital fund focusing on low-temperature technology and nuclear fusion [11] Group 2: Financial Performance and Regulatory Approvals - 复星医药's subsidiary received FDA approval for a biosimilar drug, with applications pending in China and Europe [21] - 长春高新 received approval for a clinical trial of a new growth hormone drug, with no similar products currently available in China [20] - 海辰药业 obtained a drug registration certificate for a new injection product [22] - 上海机场 reported a 12.46% year-on-year increase in passenger throughput for October [23] Group 3: Shareholder Actions - 深桑达 A plans to publicly transfer 80% of a subsidiary's shares with a minimum price of 1.857 billion yuan [12] - 中电港's major shareholder reduced its stake by 1% between October 31 and November 13 [15] - 康龙化成's major shareholders plan to collectively reduce their holdings by up to 1.5% [16] - 科兴制药's controlling shareholder intends to transfer 5% of its shares [17]

Group 1 - The core point of the article is that Kew Flower Pharmaceutical Co., Ltd. has received a drug registration certificate for Compound Polyethylene Glycol (3350) Electrolyte Powder from the National Medical Products Administration [1] - Kew Flower Pharmaceutical's revenue composition for the first half of 2025 shows that the pharmaceutical industry accounts for 99.61% of total revenue, while other businesses contribute only 0.39% [1] - As of the report date, Kew Flower Pharmaceutical has a market capitalization of 8.8 billion yuan [1]

Core Viewpoint - Lier Chemical (002737.SZ) announced that its controlling shareholder, Jiuyuan Investment Holding Group Co., Ltd., plans to transfer 160 million shares, representing 20% of the company's total equity, through a public solicitation transfer [1] Group 1 - Jiuyuan Group currently holds 23.78% of Lier Chemical's shares [1] - The transfer involves non-restricted legal person shares [1] - Concurrently, the third largest shareholder, Sichuan Huacai Technology Co., Ltd., plans to transfer 28.0153 million shares, accounting for 3.5% of the total equity, also through a public solicitation transfer [1] Group 2 - Huacai Technology currently holds 8.42% of Lier Chemical's shares [1] - Both transfers are in accordance with the relevant regulations of the State-owned Assets Supervision and Administration [1] - The shares being transferred are also non-restricted legal person shares [1]

Core Viewpoint - The company has received a drug registration certificate from the National Medical Products Administration for a new medication aimed at treating chronic constipation in children aged 1 to 11 years old, as well as fecal impaction in children aged 5 to 11 years old [1] Group 1 - The drug, a compound polyethylene glycol (3350) electrolyte solution, is specifically designed for pediatric use [1] - The approval indicates a potential expansion in the company's product offerings within the pediatric healthcare market [1]

Core Viewpoint - The company has received the drug registration certificate for Compound Polyethylene Glycol (3350) Electrolyte Powder from the National Medical Products Administration, which will enable it to accelerate the mass production and market launch of the new product [1] Group 1 - The company plans to expand its product matrix and optimize its product structure layout following the approval [1] - The company aims to leverage its brand resource advantages to enhance market competitiveness [1]

证券代码：002737 证券简称：葵花药业 公告编号：2025-073 葵花药业集团股份有限公司 关于复方聚乙二醇(3350)电解质散 获得药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 9、适应症：（1）用于治疗 1 岁至 11 岁儿童慢性便秘。（2）用于治疗 5 岁 至 11 岁儿童粪便嵌塞，即顽固性便秘伴直肠和/或结肠粪块堆积。 1 1、药品通用名称：复方聚乙二醇（3350）电解质散 2、主要成份：聚乙二醇 3350、氯化钠、氯化钾、碳酸氢钠 3、申请事项：药品注册(境内生产) 4、规格：6.9g/袋 5、注册分类：化学药品 3 类 6、处方药/非处方药：处方药 7、药品批准文号：国药准字 H20255906 10、上市许可持有人及生产企业：葵花药业集团（唐山）生物制药有限公司 二、风险提示 复方聚乙二醇（3350）电解质散取得《药品注册证书》后，公司将加速推进 新产品的量产与市场投放，进一步拓展产品矩阵，优化产品结构布局，依托品牌 资源优势，提升市场竞争力。药品上市推广受国家政策、市场环境等因素影响， 销售业绩具有不确定性。敬请广大 ...

Core Viewpoint - The company has received a drug registration certificate for Compound Polyethylene Glycol (3350) Electrolyte Powder from the National Medical Products Administration, which will enable it to accelerate mass production and market launch of the new product [1] Group 1 - The registration certificate allows the company to expand its product matrix and optimize its product structure layout [1] - The company aims to leverage its brand resource advantages to enhance market competitiveness [1]

Core Viewpoint - The company announced that its subsidiary, Kewang Pharmaceutical Group (Tangshan) Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the registration of a new drug, Compound Polyethylene Glycol (3350) Electrolyte Powder [1] Group 1 - The newly approved drug's main ingredients include polyethylene glycol 3350, sodium chloride, potassium chloride, and sodium bicarbonate [1] - The drug is classified as a Class 3 chemical drug and is categorized as a prescription medication [1] - The product specification is 6.9g per bag [1]

Core Viewpoint - The company, Kewang Pharmaceutical, has received approval from the National Medical Products Administration for its drug, Compound Polyethylene Glycol (3350) Electrolyte Powder, which is aimed at treating chronic constipation in children aged 1 to 11 and fecal impaction in children aged 5 to 11 [1] Group 1 - The drug is indicated for the treatment of chronic constipation in children aged 1 to 11 years [1] - The drug is also indicated for treating fecal impaction, specifically in children aged 5 to 11 years, which involves stubborn constipation accompanied by rectal and/or colonic fecal mass accumulation [1]